Abstract
BackgroundHigh expression of aldehyde dehydrogenase 1 (ALDH1) has been confirmed in many tumors. This enzyme plays an important role in tumor proliferation, metastasis, and drug resistance. However, in the case of papillary thyroid carcinoma (PTC), the relationship between ALDH1 expression and prognosis remains unknown.MethodWe used tissue microarrays to evaluate ALDH1A1 expression in 247 surgically resected PTC specimens by immunochemistry, and correlated the findings with the clinicopathological parameters.ResultALDH1A1 levels were significantly higher than in normal thyroid tissues. Moreover, ALDH1A1 overexpression was significantly associated with extrathyroid extension (P = 0.001), pT status (P < 0.001), pN status (P = 0.016) and TNM stage (P < 0.001). The Kaplan-Meier survival analysis suggested that high ALDH1A1 expression reflects a poorer lymph node recurrence-free survival (LN-RFS) and distant recurrence-free survival (DRFS) in PTC patients, as compared with patients having low ALDH1A1 expression. Multivariate analysis confirmed the ALDH1A1 expression was an independent prognostic factor for LN-RFS and DRFS in PTC patients.ConclusionIn conclusion, high ALDH1A1 expression correlates with poor survival in PTC patients.
Highlights
High expression of aldehyde dehydrogenase 1 (ALDH1) has been confirmed in many tumors
In conclusion, high ALDH1A1 expression correlates with poor survival in papillary thyroid carcinoma (PTC) patients
Extrathyroid invasion of the tumor was seen in 73 patients (29.5%) and lymph node metastasis was positive in 76 patients (30.7%)
Summary
High expression of aldehyde dehydrogenase 1 (ALDH1) has been confirmed in many tumors. This enzyme plays an important role in tumor proliferation, metastasis, and drug resistance. In the case of papillary thyroid carcinoma (PTC), the relationship between ALDH1 expression and prognosis remains unknown. A common endocrine malignancy, is the fifth most common cancer in women. The incidence of thyroid cancer has shown a rising trend [1]. PTC displays an indolent course and shows a ten-year survival rate of approximately 80%. This does not mean that thyroid carcinoma cannot be progressive [3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
